The coming fiscal crisis: Nephrology in the line of fire

Clinical Journal of the American Society of Nephrology

Volumn 8, Issue 7, 2013, Pages 1252-1257

  Andersen, Martin J ^a   Friedman, Allon N ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE;

ARTICLE; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DIALYSIS; DISEASE COURSE; GLOMERULUS FILTRATION RATE; GOVERNMENT; HEALTH CARE COST; HELATH CARE POLICY; HUMAN; NEPHROLOGY; PERITONEAL DIALYSIS; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SURVIVAL RATE; TREATMENT OUTCOME;

COST SAVINGS; COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HEALTH CARE RATIONING; HEALTH CARE REFORM; HEALTH POLICY; HEALTH SERVICES ACCESSIBILITY; HUMANS; KIDNEY FAILURE, CHRONIC; MEDICARE; NEPHROLOGY; QUALITY OF HEALTH CARE; QUALITY-ADJUSTED LIFE YEARS; RENAL REPLACEMENT THERAPY; UNITED STATES;

EID: 84879806378     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.00790113     Document Type: Article

References (84)

1. Catlin A, Cowan C, Hartman M, Heffler S; National Health Expenditure Accounts Team: National health spending in 2006: a year of change for prescription drugs. Health Aff (Millwood) 27: 14-29, 2008.
2. Centers for Medicare & Medicaid Services: 2012 Annual Report of the Boards of Trustees of the Federal Hospital Insurance and Federal Supplementary Medical Insurance Trust Funds. Available at: http://www.cms.gov/Research-Statistics-Data-and-Systems/ Statistics-Trends-and-Reports/ReportsTrustFunds/Downloads/ TR2012.pdf. Accessed April 8, 2013.
3. Cox C,Archer B:Why $16 trillion only hints at the trueU.S. debt. Wall Street Journal. November 26, 2012. Available at: http://online.wsj.com/article/SB10001424127887323353204578127374039087636.html?mod=googlenews_wsj. Accessed April 8, 2013.
4. Congressional Budget Office: The budget and economic outlook: fiscal years 2012 to 2022. January 2012. Available at: http://www.cbo.gov/sites/default/files/cbofiles/attachments/01-31-2012_Outlook.pdf. Accessed April 8, 2013.
5. Cohn D, Taylor P: Baby boomers approach age 65-glumly. Pew Research Social & Demographic Trends. December 20, 2010. Available at: http://pewresearch.org/pubs/1834/baby-boomersold-age-downbeat-pessimism. Accessed April 8, 2013.
6. Nissenson AR, Maddux FW, Velez RL, Mayne TJ, Parks J: Accountable care organizations and ESRD: The time has come. AmJ Kidney Dis 59: 724-733, 2012.
7. Gold J: FAQ on ACOs: accountable care organizations, explained. Kaiser Health News. October 21, 2011. Available at: http://www.kaiserhealthnews.org/stories/2011/january/13/ aco-accountable-care-organization-faq.aspx. Accessed April 8, 2013.
8. Centers for Medicare & Medicaid Services: Center for Medicare and Medicaid Innovation. Comprehensive ESRD care (CEC) model. Available at: http://innovation.cms.gov/Files/x/CEC-rfa.pdf. Accessed April 8, 2013.
9. The Patient Protection and Affordable Care Act. Available at: http://dpc.senate.gov/healthreformbill/healthbill52.pdf. Accessed April 8, 2013.
10. Rattner S: Beyond Obamacare. New York Times. September 16, 2012. Available at: http://www.nytimes.com/2012/09/17/opinion/health-care-reform-beyond-obamacare.html. Accessed April 8, 2013.
11. U.S. Renal Data System: USRDS 2011 Report. Costs of ESRD. Available at: http://www.usrds.org/2011/pdf/v2_ch011_11.pdf. Accessed April 8, 2013.
12. Fleck LM: The costs of caring: Who pays? Who profits? Who panders? Hastings Cent Rep 36: 13-17, 2006.
13. LevinskyNG: The organization ofmedical care. Lessons from the Medicare end stage renal disease program. N Engl J Med 329: 1395-1399, 1993.
14. National Institute for Health and Care Excellence: Measuring effectiveness and cost effectiveness: the QALY. April 20, 2010. Available at: http://www.nice.org.uk/newsroom/features/measuringeffectivenessandcosteffectivenesstheqaly.jsp. Accessed April 8, 2013.
15. Neumann PJ, Zinner DE, Wright JC: Are methods for estimating QALYs in cost-effectiveness analyses improving? Med Decis Making 17: 402-408, 1997.
16. Ferguson BM, Keown PA: An introduction to utility measurement in health care. Infect Control Hosp Epidemiol 16: 240-247, 1995.
17. Claxton K, Sculpher M, Culyer A, McCabe C, Briggs A, Akehurst R, Buxton M, Brazier J: Discounting and cost-effectiveness in NICE - stepping back to sort out a confusion. Health Econ 15: 1-4, 2006.
18. Grosse SD: Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res 8: 165-178, 2008.
19. Lee CP, Chertow GM, Zenios SA: An empiric estimate of the value of life: Updating the renal dialysis cost-effectiveness standard. Value Health 12: 80-87, 2009.
20. Neumann PJ, Rosen AB, Weinstein MC: Medicare and costeffectiveness analysis. N Engl J Med 353: 1516-1522, 2005.
21. Chambers JD, Neumann PJ, Buxton MJ: Does Medicare have an implicit cost-effectiveness threshold? Med Decis Making 30: E14-E27, 2010.
22. Gillick MR: Medicare coverage for technological innovations- time for new criteria? N Engl J Med 350: 2199-2203, 2004.
23. U.S. Renal Data System: USRDS 2011 Report: Incidence, prevalence, patient characteristics, and treatment modalities. Available at: http://www.usrds.org/2011/pdf/v2_ch01_11.pdf. Accessed April 8, 2013.
24. Kurella M, Covinsky KE, Collins AJ, Chertow GM: Octogenarians and nonagenarians starting dialysis in the United States. Ann Intern Med 146: 177-183, 2007.
25. Kurella Tamura M, Covinsky KE, Chertow GM, Yaffe K, Landefeld CS, McCulloch CE: Functional status of elderly adults before and after initiation of dialysis. N Engl J Med 361: 1539-1547, 2009.
26. Teerawattananon Y, Mugford M, Tangcharoensathien V: Economic evaluation of palliative management versus peritoneal dialysis and hemodialysis for end-stage renal disease: Evidence for coverage decisions in Thailand. Value Health 10: 61-72, 2007.
27. Murtagh FEM, Marsh JE, Donohoe P, EkbalNJ, Sheerin NS,Harris FE: Dialysis or not? A comparative survival study of patients over 75 years with chronic kidney disease stage 5. Nephrol Dial Transplant 22: 1955-1962, 2007.
28. Chandna SM, Da Silva-Gane M, Marshall C, Warwicker P, Greenwood RN, Farrington K: Survival of elderly patients with stage 5 CKD: Comparison of conservativemanagement and renal replacement therapy. Nephrol Dial Transplant 26: 1608-1614, 2011.
29. Mau LW, Liu J, Qiu Y, Guo H, Ishani A, Arneson TJ, Gilbertson DT, Dunning SC, Collins AJ: Trends in patient characteristics and firstyear medical costs of older incident hemodialysis patients, 1995- 2005. Am J Kidney Dis 55: 549-557, 2010.
30. Grun RP, Constantinovici N, Normand C, Lamping DL; North ThamesDialysis Study Group: Costs of dialysis for elderly people in the UK. Nephrol Dial Transplant 18: 2122-2127, 2003.
31. U.S. Renal Data Service: USRDS 2012 Report: Incidence, prevalence, patient characterisitics, and modality. Available at: http://www.usrds.org/2012/pdf/v2_ch1_12.pdf.
32. Rosansky SJ, Clark WF, Eggers P, Glassock RJ: Initiation of dialysis at higher GFRs: Is the apparent rising tide of early dialysis harmful or helpful? Kidney Int 76: 257-261, 2009.
33. Rosansky SJ, Eggers P, Jackson K, Glassock R, Clark WF: Early start of hemodialysismay be harmful. Arch Intern Med 171: 396-403, 2011.
34. Susantitaphong P, Altamimi S, Ashkar M, Balk EM, Stel VS, Wright S, Jaber BL: GFR at initiation of dialysis and mortality in CKD: A meta-analysis. Am J Kidney Dis 59: 829-840, 2012.
35. Bonomini V, Albertazzi A, Vangelista A, Bortolotti GC, Stefoni S, Scolari MP: Residual renal function and effective rehabilitation in chronic dialysis. Nephron 16: 89-102, 1976.
36. Bonomini V, Feletti C, Scolari MP, Stefoni S: Benefits of early initiation of dialysis. Kidney Int Suppl 17[Suppl 17]: S57-S59, 1985.
37. Kidney Disease Outcomes Quality Initiative: KDOQI 2006 Updates on hemodialysis and peritoneal dialysis adequacy and vascular access. Available at: http://www.kidney.org/professionals/kdoqi/pdf/12-50-0210_JAG_DCP_Guidelines-HD_Oct06_SectionA_ofC.pdf.
38. Traynor JP, Simpson K, Geddes CC, Deighan CJ, Fox JG: Early initiation of dialysis fails to prolong survival in patients with endstage renal failure. J Am Soc Nephrol 13: 2125-2132, 2002.
39. Cooper BA, Branley P, Bulfone L, Collins JF, Craig JC, Fraenkel MB, Harris A, Johnson DW, Kesselhut J, Li JJ, Luxton G, Pilmore A, Tiller DJ, Harris DC, Pollock CA; IDEAL Study: A randomized, controlled trial of early versus late initiation of dialysis. N Engl J Med 363: 609-619, 2010.
40. Harris A, Cooper BA, Li JJ, Bulfone L, Branley P, Collins JF, Craig JC, Fraenkel MB, Johnson DW, Kesselhut J, Luxton G, Pilmore A, Rosevear M, Tiller DJ, Pollock CA, Harris DC: Cost-effectiveness of initiating dialysis early: A randomized controlled trial. Am J Kidney Dis 57: 707-715, 2011.
41. Just PM, Riella MC, Tschosik EA, Noe LL, Bhattacharyya SK, de Charro F: Economic evaluations of dialysis treatment modalities. Health Policy 86: 163-180, 2008.
42. Shih YCT, Guo A, Just PM, Mujais S: Impact of initial dialysis modality and modality switches on Medicare expenditures of end-stage renal disease patients. Kidney Int 68: 319-329, 2005.
43. Khawar O, Kalantar-Zadeh K, Lo WK, Johnson D, Mehrotra R: Is the declining use of long-term peritoneal dialysis justified by outcome data? Clin J Am Soc Nephrol 2: 1317-1328, 2007.
44. Jiwakanon S, Chiu YW, Kalantar-Zadeh K, Mehrotra R: Peritoneal dialysis: An underutilized modality. Curr Opin Nephrol Hypertens 19: 573-577, 2010.
45. Julius M, Kneisley JD, Carpentier-Alting P, Hawthorne VM, Wolfe RA, Port FK: A comparison of employment rates of patients treated with continuous ambulatory peritoneal dialysis vs incenter hemodialysis (Michigan End-Stage Renal Disease Study). Arch Intern Med 149: 839-842, 1989.
46. Sennfält K, Magnusson M, Carlsson P: Comparison of hemodialysis and peritoneal dialysis-a cost-utility analysis. Perit Dial Int 22: 39-47, 2002.
47. Termorshuizen F, Korevaar JC, Dekker FW, Van Manen JG, Boeschoten EW, Krediet RT; Netherlands Cooperative Study on the Adequacy of Dialysis Study Group: Hemodialysis and peritoneal dialysis: Comparison of adjusted mortality rates according to the duration of dialysis: analysis of The Netherlands Cooperative Study on the Adequacy of Dialysis 2. J AmSoc Nephrol 14: 2851-2860, 2003.
48. Jaar BG, Coresh J, Plantinga LC, Fink NE, Klag MJ, Levey AS, Levin NW, Sadler JH, Kliger A, Powe NR: Comparing the risk for death with peritoneal dialysis and hemodialysis in a national cohort of patients with chronic kidney disease. Ann Intern Med 143: 174-183, 2005.
49. Mehrotra R, Chiu YW, Kalantar-Zadeh K, Bargman J, Vonesh E: Similar outcomes with hemodialysis and peritoneal dialysis in patients with end-stage renal disease. Arch Intern Med 171: 110-118, 2011.
50. Korevaar JC, Feith GW, Dekker FW, van Manen JG, Boeschoten EW, Bossuyt PM, Krediet RT; NECOSAD Study Group: Effect of starting with hemodialysis compared with peritoneal dialysis in patients new on dialysis treatment: A randomized controlled trial. Kidney Int 64: 2222-2228, 2003.
51. Rubin HR, Fink NE, Plantinga LC, Sadler JH, Kliger AS, Powe NR: Patient ratings of dialysis care with peritoneal dialysis vs hemodialysis. JAMA 291: 697-703, 2004.
52. Kutner NG, Zhang R, Barnhart H, Collins AJ: Health status and quality of life reported by incident patients after 1 year on haemodialysis or peritoneal dialysis. Nephrol Dial Transplant 20: 2159-2167, 2005.
53. Kontodimopoulos N, Niakas D: An estimate of lifelong costs and QALYs in renal replacement therapy based on patients' life expectancy. Health Policy 86: 85-96, 2008.
54. U.S. Renal Data System: USRDS 2010 Report: Treatment modalities. Available at: http://www.usrds.org/2010/pdf/v2_04.pdf.
55. Culleton BF, Walsh M, Klarenbach SW, Mortis G, Scott-Douglas N, Quinn RR, Tonelli M, Donnelly S, Friedrich MG, Kumar A, Mahallati H, Hemmelgarn BR, Manns BJ: Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: A randomized controlled trial. JAMA 298: 1291-1299, 2007.
56. Chertow GM, Levin NW, Beck GJ, Depner TA, Eggers PW, Gassman JJ, Gorodetskaya I, Greene T, James S, Larive B, Lindsay RM, Mehta RL, Miller B, Ornt DB, Rajagopalan S, Rastogi A, Rocco MV, Schiller B, Sergeyeva O, Schulman G, Ting GO, Unruh ML, Star RA, Kliger AS; FHN Trial Group: In-center hemodialysis six times per week versus three times per week. N Engl J Med 363: 2287-2300, 2010.
57. Economic Report: Home Haemodialysis. Available at: http://www.quantafs.com/img/uploads/files/documents/CEP10063_%20economic%20report_home%20haemodialysis.pdf. Accessed April 8, 2013.
58. McFarlane PA, Bayoumi AM, Pierratos A, Redelmeier DA: The quality of life and cost utility of home nocturnal and conventional in-center hemodialysis. Kidney Int 64: 1004-1011, 2003.
59. Miskulin DC, Meyer KB, Athienites NV, Martin AA, Terrin N, Marsh JV, Fink NE, Coresh J, Powe NR, Klag MJ, Levey AS: Comorbidity and other factors associatedwith modality selection in incident dialysis patients: The CHOICE Study. Choices for Healthy Outcomes in Caring for End-Stage Renal Disease. Am J Kidney Dis 39: 324-336, 2002.
60. Rubin DB: Estimating causal effects from large data sets using propensity scores. Ann Intern Med 127: 757-763, 1997.
61. Berger A, Edelsberg J, Inglese GW, Bhattacharyya SK, Oster G: Cost comparison of peritoneal dialysis versus hemodialysis in end-stage renal disease. Am J Manag Care 15: 509-518, 2009.
62. U.S. Renal Data System: USRDS 2012 Report: Costs of ESRD. Available at: http://www.usrds.org/2012/pdf/v2_ch11_12.pdf.
63. U.S. Renal Data System: USRDS 2011 Report: Mortality. Available at: http://www.usrds.org/2011/pdf/v2_ch05_11.pdf.
64. Health Resources and Services Administration, Scientific Registry of Transplant Recipients: Scientific registry of transplant recipients: 2010 Report for Kidney Transplantation. Available at: http://srtr.transplant.hrsa.gov/annual_reports/2010/pdf/01_kidney_11.pdf.
65. Blumberg JM, Gritsch H, Veale JL: Kidney paired donation: Advancements and future directions. Curr Opin Organ Transplant 16: 380-384, 2011.
66. Johns Hopkins Medicine: Paired kidney exchange. Available at: http://www.hopkinsmedicine.org/transplant/programs/kidney/incompatible/paired_kidney_exchange.html.
67. Henderson D: Onmarriage, kidneys and the EconomicsNobel. Wall Street Journal October 15, 2012. Available at: http://online.wsj.com/article/SB10000872396390443675404578058773182478536.html. Accessed April 8, 2013.
68. Rees MA, Schnitzler MA, Zavala EY, Cutler JA, Roth AE, Irwin FD, Crawford SW, Leichtman AB: Call to develop a standard acquisition charge model for kidney paired donation. Am J Transplant 12: 1392-1397, 2012.
69. International Summit on Transplant Tourism and Organ Trafficking: The Declaration of Istanbul on organ trafficking and transplant tourism. Clin J Am Soc Nephrol 3: 1227-1231, 2008.
70. Ghods AJ, Savaj S: Iranian model of paid and regulated livingunrelated kidney donation. Clin J Am Soc Nephrol 1: 1136-1145, 2006.
71. Zargooshi J: Iranian kidney donors: motivations and relations with recipients. J Urol 165: 386-392, 2001.
72. Griffin A: Kidneys on demand. BMJ 334: 502-505, 2007.
73. Matas AJ, Schnitzler M: Payment for living donor (vendor) kidneys: A cost-effectiveness analysis. Am J Transplant 4: 216-221, 2004.
74. Hippen B, Ross LF, Sade RM: Saving lives is more important than abstract moral concerns: Financial incentives should be used to increase organ donation. Ann Thorac Surg 88: 1053-1061, 2009.
75. Barnieh L, Klarenbach S, Gill JS, Caulfield T, Manns B: Attitudes toward strategies to increase organ donation: Views of the general public and health professionals. Clin J Am Soc Nephrol 7: 1956-1963, 2012.
76. Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, Allon M, Bailey J, Delmez JA, Depner TA, Dwyer JT, Levey AS, Levin NW, Milford E, Ornt DB, Rocco MV, Schulman G, Schwab SJ, Teehan BP, Toto R; Hemodialysis (HEMO) Study Group: Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 347: 2010-2019, 2002.
77. Paniagua R, Amato D, Vonesh E, Correa-Rotter R, Ramos A, Moran J, Mujais S; Mexican Nephrology Collaborative Study Group: Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis:ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol 13: 1307-1320, 2002.
78. Wanner C, Krane V, März W, Olschewski M, Mann JF, Ruf G, Ritz E; German Diabetes and Dialysis Study Investigators: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353: 238-248, 2005.
79. Fellström BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Grönhagen-Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, Süleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wüthrich RP, Gottlow M, Johnsson E, Zannad F; AURORA Study Group: Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360: 1395-1407, 2009.
80. Chertow GM, Block GA, Correa-Rotter R, Drüeke TB, Floege J, Goodman WG, Herzog CA, Kubo Y, London GM, Mahaffey KW, Mix TC, Moe SM, Trotman ML, Wheeler DC, Parfrey PS; EVOLVE Trial Investigators: Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis.N Engl J Med 367: 2482-2494, 2012.
81. Covic A, Gusbeth-Tatomir P, Goldsmith D: Negative outcome studies in end-stage renal disease: How dark are the storm clouds? Nephrol Dial Transplant 23: 56-61, 2008.
82. Formentini I, Bobadilla M, Haefliger C, Hartmann G, Loghman- Adham M, Mizrahi J, Pomposiello S, Prunotto M, Meier M: Current drug development challenges in chronic kidney disease (CKD)-identification of individualized determinants of renal progression and premature cardiovascular disease (CVD). Nephrol Dial Transplant 27: iii81-88, 2012.
83. Wouldn't it be NICE to consider patients' views when rationing health careBMJ 338: b85, 2009.
84. Rothenberg LS: Withholding and withdrawing dialysis from elderly ESRD patients: part 1 - a historical view of the clinical experience. Geriatr Nephrol Urol 2: 109-117, 1992